^
Association details:
| Biomarker: | ARID1A mutation |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | NXP900 (Src kinase inhibitor, YES1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Title:
FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma
Published date:
12/01/2022
Excerpt:
Nuvectis Pharma, Inc...announced that the U.S. Food and Drug Administration (the "FDA") has granted Fast Track Designation to NXP800 for the treatment of platinum-resistant, ARID1A-mutated ovarian carcinoma.
Source:
Title:
3326 / 4 - Uncovering the molecular mechanisms which predict sensitivity to a novel src kinase inhibitor NXP900 to inform personalized healthcare strategies
Published date:
03/09/2022
Excerpt:
Among the most sensitive cell line subtypes are, squamous cell carcinoma, Arid1A mutant ovarian clear cell carcinoma and subtypes of breast luminal A and triple negative breast cancer cell lines. HER2+ breast cancer lines appear insensitive to NXP900 indicating HER2 as a potential driver of resistance to NXP900....Our result provide an indication of patient subgroups which may exhibit optimal therapeutic response to NXP900...
